Additional Information - The Alzheimer’s Drug Discovery Foundation invites Letters of Intent for its Program to Accelerate Clinical Trials. The goal of the program is to support investigational new drug (IND)-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease and related dementias. In particular, the Program to Accelerate Clinical Trials (PACT) program will fund: Early-Stage Human Clinical Trials: Including phase 0 micro- or sub-therapeutic-dosing studies; phase 1 trials in healthy subjects; and biomarker-based proof-of-concept studies (generally phase 1b or phase 2a trials) designed to assess target engagement and downstream pharmacologic effects. Regulatory Studies: Including non-GLP and GLP pharmacology and toxicology studies, pre-formulation, and GMP manufacture required for investigational new drug and clinical trial authorization preclinical packages. Funding is available to prepare traditional and exploratory IND applications; long-term toxicology studies to enable longer-term dosing in phase 2 trials; and GMP manufacturing and testing of clinical grade drug required to move into phase 2 or phase 3 trials. Novel repurposed and repositioned drugs and natural products and devices will be considered. Therapeutic modalities of interest include small molecules, peptides, antibodies, gene therapies, antisense oligonucleotides, and stem cells. Other non-pharmacologic interventions, such as diet, meditation, and exercise, will not be considered. Current target areas of interest include epigenetics, inflammation, mitochondria and metabolic function, neuroprotection, proteostasis, synaptic activity and neurotransmitters, vascular function, aging targets (e.g., senescent cells), and other novel targets or pathways that are supported by compelling evidence demonstrating a rational biological connection to the disease process. Up to $3 million will be awarded based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged. Letters of Intent must be received no later than February 4, 2022, and, selected applicants will be invited to submit a full proposal by April 8, 2022. Please contact if you are interested in applying to this opportunity.